IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1251-1275 out of 1325.

<< < 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 > >>

Public Release: 5-Nov-2015
Cell
DNA strands often 'wiggle' as part of genetic repair
New research indicates that every time a double-stranded break occurs in DNA strands, the damaged ends move about during repair. Scientists believe that a better understanding of this mysterious mechanism could improve the use of cancer treatments, some of which manipulate DNA repair in malignant cells.

Contact: Wynne Parry
wparry@rockefeller.edu
212-327-7789
Rockefeller University

Public Release: 5-Nov-2015
Science
Vitamin C stresses and kills mutant cancer cells
Colorectal cancer cells with certain mutations 'handle' vitamin C differently than other cells, and this difference ultimately kills them, a new study shows.

Contact: Natasha Pinol
scipak@aaas.org
202-326-6440
American Association for the Advancement of Science

Public Release: 5-Nov-2015
Science
Gut microbiome drives success of immunotherapy
Why some patients respond well to immunotherapy and others do not is unclear, but two new studies now provide evidence that the gut microbiome can play a role.

Contact: Natasha Pinol
scipak@aaas.org
202-326-6440
American Association for the Advancement of Science

Public Release: 5-Nov-2015
Molecular Cancer Research
New breast cancer stem cell clues may help develop therapeutics
Researchers have identified a new regulatory pathway that may play an important role in basal-like breast cancer, a particularly aggressive form of breast cancer often referred to as 'triple negative.' This pathway may serve as a target for the development of an effective therapeutic.
US Department of Defense Breast Cancer Research Program

Contact: Gina DiGravio
ginad@bu.edu
617-638-8480
Boston University Medical Center

Public Release: 5-Nov-2015
Science
Gut bacteria can dramatically amplify cancer immunotherapy
Introducing one type of bacteria into the digestive tracts of mice with melanoma can boost the ability of the animal's immune systems to attack tumor cells. The gains were comparable to treatment with anti-cancer drugs known as checkpoint inhibitors. The combination of bacteria and injections with anti-PD-L1 antibody nearly abolished tumor outgrowth.
Melanoma Research Alliance, National Institutes of Health

Contact: John Easton
john.easton@uchospitals.edu
773-795-5225
University of Chicago Medical Center

Public Release: 5-Nov-2015
Advanced Breast Cancer Third International Consensus Conference
Higher insulin is an independent prognostic factor in advanced breast cancer
Patients with breast cancer that has spread to other parts of the body (metastasized) and who have higher insulin levels than normal, but are not diabetic, have a significantly worse prognosis compared with those with normal insulin levels.
Italian Association for Cancer Research

Contact: Mary Rice
mary.rice@riceconseil.eu
European School of Oncology

Public Release: 5-Nov-2015
Science
Stem-cell scientists redefine how blood is made
Stem-cell scientists led by Dr. John Dick have discovered a completely new view of how human blood is made, upending conventional dogma from the 1960s.
Canadian Institutes for Health Research, Canadian Cancer Society, Terry Fox Foundation, Genome Canada/Ontario Genomics Institute, Ontario Institute of Cancer Research, Canada Research Chair, Ontario Ministry of Health and Long-term Care, and others

Contact: Jane Finlayson
jane.finlayson@uhn.ca
416-946-2846
University Health Network

Public Release: 5-Nov-2015
Scientific Reports
New research could help in the fight against infection, cancer and allergies
New research has uncovered an important mechanism in the drive to understand immunological processes that protect us against infection, allergy and cancer.
Cancer Research UK

Contact: Glenn Harris
G.Harris@soton.ac.uk
44-023-805-93212
University of Southampton

Public Release: 5-Nov-2015
JAMA Oncology
First precision medicine trial in cancer prevention identifies chemoprevention strategy
A team of scientists report that a genetic biomarker called loss of heterozygosity is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer. The findings, published Nov. 5 by the Journal of the American Medical Association Oncology, present a new tool that could be used to identify patients most likely to benefit from chemoprevention -- and may be applicable to preventing other types of cancer.
OSI Pharmaceuticals, National Cancer Institute, Cancer Prevention and Research Institute of Texas, Conquer Cancer Foundation

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 5-Nov-2015
Advanced Breast Cancer Third International Consensus Conference
Medicines for breast cancer: The affordability controversy
New and better drugs to treat diseases such as advanced breast cancer will have little effect on improving patient outcomes if a country does not have good health-care structures in place.

Contact: Emma Mason
wordmason@mac.com
European School of Oncology

Public Release: 5-Nov-2015
Cell
Researchers identify new route for release of steroid hormones
Little is known about the mechanisms that regulate the release of steroid hormones from endocrine tissues. The commonly accepted understanding, noted in textbooks, is that simple diffusion is at work. But new research by a team led by a UC Riverside entomologist challenges this textbook view. The researchers report that in fruit flies, the focus of their study, the release of the steroid hormone 'ecdysone' is tightly regulated by signaling pathways in the cell.
Japan Society for the Promotion of Science, National Institutes of Health

Contact: Iqbal Pittalwala
iqbal@ucr.edu
951-827-6050
University of California - Riverside

Public Release: 4-Nov-2015
Nature Biotechnology
'JEDI' technology awakens new understanding of how immune system works
Scientists at Mount Sinai create immune cells that visibly kill cancer and pathogen infected cells

Contact: Sid Dinsay
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 4-Nov-2015
Advanced Breast Cancer Third International Consensus Conference
Stop the damaging messages about advanced breast cancer and include us in your discussions
Organizations that issue 'damaging messages' about advanced breast cancer need to be identified and educated to change the way they talk about the disease, a patient will tell the Advanced Breast Cancer Third International Consensus Conference. In another presentation, a second patient will say that the voices of patients needed to be included in discussions between policy makers and the medical community about whether the high costs of second and third line treatments for the disease is financially sustainable by society.

Contact: Emma Mason
wordmason@mac.com
European School of Oncology

Public Release: 4-Nov-2015
Science Translational Medicine
A way to target the Achilles heel of neuroblastoma
Australian scientists have identified a critical molecular 'feedback loop' that helps initiate and drive neuroblastoma, a cancer of the nervous system in children that is triggered in embryonal nerve cells. The research team have also identified an experimental drug, currently in clinical trials for adult cancer, with the potential to interrupt the loop and halt tumor progression.
National Health and Medical Research Council Australia, Cancer Institute NSW, Cancer Council NSW, Australian RotaryHealth/Rotary Club of Adelaide, Fund for Scientific Research Flanders, German Cancer Aid, German Ministry of Science and Education, others

Contact: Alison Heather
aheather@ccia.org.au
61-293-859-069
Children's Cancer Institute Australia

Public Release: 4-Nov-2015
170th Meeting of the Acoustical Society of America (ASA)
Sound waves levitate cells to detect stiffness changes that could signal disease
Utah Valley University physicists are literally applying rocket science to the field of medical diagnostics. With a few key changes, the researchers used a noninvasive ultrasonic technique originally developed to detect microscopic flaws in solid fuel rockets to successfully detect cell stiffness changes associated with certain cancers and other diseases. Brian Patchett will describe the group's method, which uses sound waves to manipulate and probe cells, during ASA's Fall 2015 Meeting.

Contact: John Arnst
jarnst@aip.org
301-209-3096
Acoustical Society of America

Public Release: 4-Nov-2015
Nature Communications
DNA in blood can track cancer development and response in real time
Scientists have shown for the first time that tumor DNA shed into the bloodstream can be used to track cancers in real time as they evolve and respond to treatment.
Cancer Research UK

Contact: Greg Jones
greg.jones@cancer.org.uk
44-203-469-8311
Cancer Research UK

Public Release: 4-Nov-2015
International Journal of Gynecological Cancer
CK5 marks cisplatin-resistant ovarian cancer
A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
University of Colorado AMC Department of Obstetrics and Gynecology, National Institutes of Health

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Anschutz Medical Campus

Public Release: 4-Nov-2015
PLOS ONE
Mammography screening: Only 1 in 3 women is well-informed
Only one in three women participating in Germany's mammography screening program is well-informed about it: the higher the level of education, the greater the chance of women making an informed decision. These are the results of a study that health care researchers at Bielefeld University are publishing today in the international specialist journal PLOS ONE.

Contact: Dr. Jacob Spallek
jacob.spallek@uni-bielefeld.de
49-521-106-2554
Bielefeld University

Public Release: 4-Nov-2015
Journal of Clinical Oncology
Study rejects biologic age as limiting factor for stem cell transplants
More than 40 percent of older patients with acute myeloid leukemia (AML) can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study led by oncologists at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James).
National Cancer Institute/Alliance for Clinical Trials in Oncology

Contact: Amanda Harper
amanda.harper2@osumc.edu
614-685-5420
Ohio State University Wexner Medical Center

Public Release: 4-Nov-2015
Nature Communications
'Liquid biopsy' promotes precision medicine by tracking patient's cancer
A team of researchers, including scientists from the Translational Genomics Research Institute (TGen), has reported that analyzing circulating tumor DNA (ctDNA) can track how a patient's cancer evolves and responds to treatment. In a study published today in Nature Communications, Dr. Muhammed Murtaza of TGen and Mayo Clinic, and colleagues, describe an extensive comparison between biopsy results and analysis of ctDNA in a patient with breast cancer.

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute

Public Release: 4-Nov-2015
Science Translational Medicine
Blood test picks out prostate cancer drug resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment. The new research paves the way for information from a blood test to inform prostate cancer treatment in future, with only those patients whose cancers are free of resistance mutations taking the drug, abiraterone.
Cancer Research UK, Prostate Cancer UK, NIHR Biomedical Research Centre at the Royal Marsden and The Institute of Cancer Research, University of Trento

Contact: Claire Bithell
claire.bithell@icr.ac.uk
020-715-35229
Institute of Cancer Research

Public Release: 3-Nov-2015
Mayo Clinic Proceedings
Standing and exercise linked to lower odds of obesity
Standing for at least one-quarter of the day has been linked to lower odds of obesity in a new study.

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 3-Nov-2015
Human Pathology
Simple test predicts response to chemotherapy in lung cancer patients
Scientists at Lawson Health Research Institute have found that adenocarcinoma patients who undergo chemotherapy and surgery experience significantly improved survival rates when their tumor is lacking the retinoblastoma tumor suppressor protein. This new information is very useful as it may predict which patients will respond best to chemotherapy.

Contact: Robert DeLaet
robert.delaet@lawsonresearch.com
519-685-8500 x75664
Lawson Health Research Institute

Public Release: 3-Nov-2015
Western Surgical Association Annual Meeting
Study: Only 1 in 5 US pancreatic cancer patients get this key blood test at diagnosis
Only one in five US pancreatic cancer patients receive a widely available, inexpensive blood test at diagnosis that can help predict whether they are likely to have a better or worse outcome than average and guide treatment accordingly, a Mayo Clinic study shows.
Mayo Clinic

Contact: Sharon Theimer
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 3-Nov-2015
Pediatric Blood and Cancer
Chemotherapy-induced hearing loss affects cognition in pediatric brain tumor survivors
More children are surviving malignant brain tumors than in the past, thanks to the use of intense treatments using platinum-based chemotherapy (cisplatin and high-dose carboplatin). Unfortunately, the therapy has a known side effect of permanent hearing loss, resulting from damage to the inner ear. Investigators at Children's Hospital Los Angeles now report that this type of chemotherapy may not only impact hearing, but that the hearing loss may then contribute to long-term neurocognitive deficits.
National Institutes of Health

Contact: Ellin Kavanagh
ekavanagh@chla.usc.edu
323-361-8505
Children's Hospital Los Angeles

Showing releases 1251-1275 out of 1325.

<< < 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 > >>

  Search News Releases

     

 

EurekAlert!